Murayama, Takashi, Toshiharu Oba, Shigeki Kobayashi, Noriaki Ikemoto, and Yasuo Ogawa. Postulated role of interdomain interactions within the type 1 ryanodine receptor in the low gain of Ca 2ϩ -induced Ca 2ϩ release activity of mammalian skeletal muscle sarcoplasmic reticulum.
Ryanodine receptor (RyR) type 1 (RyR1) exhibits a markedly lower gain of Ca 2ϩ -induced Ca 2ϩ release (CICR) activity than RyR type 3 (RyR3) in the sarcoplasmic reticulum (SR) of mammalian skeletal muscle (selective stabilization of the RyR1 channel), and this reduction in the gain is largely eliminated using 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonic acid (CHAPS). We have investigated whether the hypothesized interdomain interactions within RyR1 are involved in the selective stabilization of the channel using [ 3 H]ryanodine binding, single-channel recordings, and Ca 2ϩ release from the SR vesicles. Like CHAPS, domain peptide 4 (DP4, a synthetic peptide corresponding to the Leu 2442 -Pro 2477 region of RyR1), which seems to destabilize the interdomain interactions, markedly stimulated RyR1 but not RyR3. Their activating effects were saturable and nonadditive. Dantrolene, a potent inhibitor of RyR1 used to treat malignant hyperthermia, reversed the effects of DP4 or CHAPS in an identical manner. These findings indicate that RyR1 is activated by DP4 and CHAPS through a common mechanism that is probably mediated by the interdomain interactions. DP4 greatly increased [ 3 H]ryanodine binding to RyR1 with only minor alterations in the sensitivity to endogenous CICR modulators (Ca 2ϩ , Mg 2ϩ , and adenine nucleotide). However, DP4 sensitized RyR1 four-to six-fold to caffeine in the caffeine-induced Ca 2ϩ release. Thus the gain of CICR activity critically determines the magnitude and threshold of Ca 2ϩ release by drugs such as caffeine. These findings suggest that the low CICR gain of RyR1 is important in normal Ca 2ϩ handling in skeletal muscle and that perturbation of this state may result in muscle diseases such as malignant hyperthermia. (30, 31) . The RyR is also activated by Ca 2ϩ , a process known as Ca 2ϩ -induced Ca 2ϩ release (CICR) (1) . There are three distinct isoforms of RyR in mammalian tissues: RyR1-RyR3 (24, 33, 34) . The primary isoform present in the skeletal muscle of mammals is RyR1, and miniscule amounts of RyR3 are also expressed in some special cases, such as in the diaphragm and the soleus (33, 34 , and adenine nucleotides; agents modulating critical sulfhydryls of RyR1; and accessory proteins such as calmodulin and 12-kDa FK-506-binding protein (FKBP12) (12, 14, 23, 24, 29) .
In addition to such modulations, Ikemoto and Yamamoto (6) (10) , and Ca 2ϩ sparks in saponin-permeabilized fibers (32) . Importantly, replacement of arginine with cysteine in DP4 (DP4-mut, mimicking the Arg2458Cys mutation in MH) totally abolished these effects. Furthermore, cross-linking studies have shown that DP4 binds to the NH 2 -terminal region of RyR1 (37) . It was hypothesized that the two domains (NH 2 terminus and central domains) of RyR interact with each other to stabilize the closed state of the channel. In this hypothesis, a mutation in either domain would weaken the domain-domain interaction, resulting in channel destabilization and enhanced channel activity. Similarly, exogenous domain peptides (e.g., DP4) interfere with the domaindomain interaction by competing with the corresponding domain for the mating domain, leading to destabilization of the RyR channel.
We have recently shown that the specific activity of Ca 2ϩ -dependent [ 3 H]ryanodine binding to RyR1 is significantly lower than that to RyR3, suggesting that the gain of CICR activity of RyR1 is reduced because of selective stabilization in the native SR vesicles of mammalian skeletal muscle (19) . This selective stabilization also occurs in frog skeletal muscle, where the CICR gain of ␣-RyR, the homolog to RyR1, is much lower than that of ␤-RyR, the homolog to RyR3 (20) . Interestingly, the stabilization is more pronounced in ␣-RyR in the frog (Ͻ4% of ␤-RyR) than in RyR1 in mammals (Ͻ15% of RyR3). The selective stabilization of RyR1 was attributed to two independent mechanisms: FKBP12 and 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid (CHAPS)-sensitive mechanisms (19) . The latter mechanism seemed to play a major role (Ͼ70%), but the precise mechanism is not known.
In this study, we hypothesized that the interdomain interaction may account for the selective stabilization of the RyR1 channel, especially for the CHAPS-sensitive process. To test this hypothesis, we examined the effect of DP4 on the activity of RyR1. The results suggest that DP4 and CHAPS share a common mechanism in enhancing the CICR activity of RyR1, supporting our hypothesis. This conclusion is further supported by the finding of the present study that dantrolene (or its analog, azumolene) inhibits both DP4-and CHAPS-induced channel activation in the identical manner (e.g., by showing essentially identical concentration dependence of inhibition). We also found that DP4 markedly enhanced caffeine sensitivity in releasing Ca 2ϩ from the SR vesicles. These results indicate that the state at a reduced gain of the CICR activity of RyR1 is important in normal Ca 2ϩ handling in skeletal muscle, and perturbation of this state may cause the channel dysfunction observed in some muscle diseases such as MH.
MATERIALS AND METHODS

Materials.
Peptides (DP4 and DP4-mut) were synthesized using a synthesizer (model 431A; Applied Biosystems, Foster City, CA) with N-(9-fluorenyl)methoxycarbonyl as the ␣-amino-protecting group, and they were purified by performing reverse-phase high-pressure liquid chromatography (36 (19) . Briefly, the SR vesicles (100 g of protein) were incubated with 8.5 nM 3 H]ryanodine bound to RyR1 and RyR3 were determined on the basis of the protein-bound radioactivity in the supernatant and the precipitated beads, respectively, after immunoprecipitating RyR3 with the anti-RyR3 antibody agarose beads (18) . For epicranial muscle SR vesicles, the protein-bound [ 3 H]ryanodine was separated by filtration through polyethyleneiminetreated Whatman GF/B filters (Whatman, Brentford, UK). In some experiments, CHAPS was added after mixing with half amounts of soybean lecithin (19) . Dantrolene and azumolene were dissolved in dimethyl sulfoxide (10 mM as a stock solution). Nonspecific radioactivity was determined in the presence of 20 M unlabeled ryanodine. Single-channel recordings. Single-channel recordings were obtained as described previously (22, 23) . Lipid bilayers consisting of a mixture of L-␣-phosphatidylethanolamine, L-␣-phosphatidyl-L-serine, and L-␣-phosphatidylcholine (5:3:2 wt/wt) in n-decane (40 mg/ml) were formed across a hole ϳ250 m in diameter in a polystyrene partition separating cis-and trans-chambers. Native SR vesicles and the purified RyR1 were prepared from rabbit back muscle, which expresses only RyR1 (17) . Channel currents were recorded in symmetrical solutions of 250 mM Cs-methanesulfonate (for the native SR vesicles) or KCl (for the purified RyR1) buffered at pH 7.4 with 20 mM HEPES-Tris at the holding potential of Ϫ40 mV (cis). Experiments were performed at 18 -22°C. Bilayers containing only a single channel were used for analysis. Channel currents amplified using an Axopatch 1D patch-clamp amplifier (Axon Instruments, Union City, CA) were filtered at 1 kHz with an eight-pole, low-pass Bessel filter and collected at 5 kHz for analysis. Mean open probability (P o) was calculated from recordings of duration Ͼ2 min using 50% threshold analysis performed with pClamp software version 6.0.4 (Axon Instruments).
Ca 2ϩ release measurements. Ca 2ϩ release from the isolated SR vesicles was fluorometrically measured by monitoring free Ca 2ϩ concentration in the solution. Bovine epicranial SR vesicles (80 g) were incubated at 25°C in a fluorometer cuvette containing 400 l of 0.17 M KCl, 20 mM MOPSO, pH 6.8, 5 mM potassium phosphate, 10 mM phosphocreatine, 2 U/ml creatine kinase, and 2 M fura-2. Fluorescence was measured using a Hitachi F-4500 fluorescence spectrophotometer with wavelength settings of 340 and 380 nm for excitation (alternating) and 510 nm for emission. The contaminating Ca 2ϩ in the solution provided a sufficient extent of Ca 2ϩ loading for Ca 2ϩ release, and therefore no Ca 2ϩ was added. Active loading of the SR vesicles with Ca 2ϩ was started by addition of 1 mM Mg-ATP, which would give rise to ϳ0.3 mM free Mg 2ϩ . Free Ca 2ϩ concentration in the cuvette declined with time and reached the steady state within 5 min. At this point, test reagents (DP4 or caffeine) were added and the changes in fura-2 fluorescence were recorded.
Statistics. The data are expressed as means Ϯ SE of n repeated experiments. Student's unpaired t-test was used to determine the significance of the differences between mean values. Figure 1A demonstrates differential effects of DP4 on the [ 3 H]ryanodine binding to RyR1 and RyR3 in bovine diaphragm muscle at 30 M Ca 2ϩ . DP4 (100 M) increased the [ 3 H]ryanodine binding to RyR1 more than fivefold compared with the control level, whereas DP4-mut almost abolished the activating effect. In contrast, DP4 and DP4-mut produced virtually no effect on RyR3. Addition of CHAPS (as a 2:1 CHAPS-soybean lecithin wt/wt mixture) also increased the [ (Fig. 1B) , consistent with our previous results (19) . These findings indicate that RyR1 is preferentially activated by DP4 or by CHAPS.
RESULTS
CHAPS-induced RyR1 channel destabilization (activation) in the mammalian skeletal muscle shares a common mechanism with channel activation by DP4.
To test the hypothesis that DP4 and CHAPS act through a common mechanism, we performed quantitative analysis of the effects of DP4 and CHAPS on [ 3 H]ryanodine binding to RyR1 using bovine epicranial muscle, in which a single isoform of RyR1 is expressed (19) . The activity was expressed as B/B max , in which B values at a specified concentration of the ligand were normalized by B max , obtained in separate experiments (see MATERIALS AND METHODS). This expression reflects apparent averaged activity of individual RyR channels (19) . Figure 2A shows the concentration-dependent activating effect of DP4 on Fig. 2A, closed circles) , whereas DP4-mut showed virtually no activating effect ( Fig. 2A, open circles) . The extent of the maximal enhancement by DP4 was nearly sevenfold (from 0.019 Ϯ 0.002 to 0.13 Ϯ 0.02), and the concentration required for half-maximal activation was ϳ50 M. (Fig. 2B, closed circles) . The maximum enhancement of B/B max by CHAPS was greater than sixfold (from 0.026 Ϯ 0.02 to 0.16 Ϯ 0.1), and the concentration required for half-maximal activation was ϳ1%. The essentially identical CHAPS concentration dependence was obtained in the range of final concentration of 0.5-2% CHAPS with the SR vesicles that had been treated with 2% CHAPS and diluted to the CHAPS concentrations indicated (Fig. 2B, open  circles) . These results suggest that the effect of CHAPS is reversible and is determined by its final concentration.
We next examined whether the combined effects of these reagents were additive or nonadditive (Fig. 3) . In the presence of 2% CHAPS in experiments in which the activation reached the maximum (see Fig. 2B ), the addition of DP4 did not cause a further increase in the activity up to 500 M. With 1% CHAPS in experiments in which the activation was about half the maximum, DP4 showed a concentration-dependent activation but the maximal level attained was almost the same as the maximum attained in the presence of 2% CHAPS. Notably, the apparent EC 50 value of DP4-induced activation was greater in the presence of 1% CHAPS than it was in its absence (from ϳ50 M in the control to ϳ100 M with 1% CHAPS), but again the maximum level remained the same. Thus the effects of DP4 and CHAPS are nonadditive. The highest attainable activation level was not due to the limitation of the assay system (e.g., saturation of [ 3 H]ryanodine binding), because even much larger values were obtained with FK-506 (see Fig.  5 ) or at higher ionic strength (data not shown). These findings support the notion that DP4 and CHAPS act on RyR1 through a common activation mechanism.
Effects of dantrolene and its analog on DP4-activated or CHAPS-activated [
3 H]ryanodine binding to RyR1. Dantrolene is an inhibitor of RyR1 used for the treatment of MH. It is widely accepted that its inhibitory effect on RyR1 is dependent on temperature and Ca 2ϩ concentration, although many diverse and conflicting results have been reported (2, 9, 26) . According to the more recent reports, dantrolene binds to the Leu 590 -Cys 609 region of RyR1 (28) and stabilizes interdomain interactions to reverse DP4-induced channel activation (7). Therefore, if DP4-and CHAPS-induced activation of RyR1 share a common mechanism mediated by destabilization of interdomain interactions, we expect that dantrolene will inhibit both DP4-and CHAPS-induced activation effects and show the identical pattern of inhibition. The ryanodine binding experiments shown in Fig. 4 were performed to test this hypothesis. Experiments were performed at 37°C instead of 25°C because dantrolene is more effective at a high temperature (2, 26) . As shown in Fig. 4A (2, 27) ; again, the extent of inhibition was identical, regardless of whether DP4 or CHAPS was used to activate ryanodine binding (Fig. 4B) .
Dissociation DP4 might have competed with the corresponding domain of RyR1 to dissociate FKBP12 from RyR1, resulting in activation of the channel. To test this possibility, we examined the effect of DP4 on the amount of the RyR1-bound FKBP12. Incubation of the SR vesicles with 100 M DP4 did not affect the amount of FKBP12 bound to the SR vesicles, whereas 10 M FK-506 completely dissociated FKBP12 from the vesicles (Fig. 5A) . No effect was observed with 100 M DP4-mut either. [ 3 H]Ryanodine binding to RyR1 in the presence of the maximally activating concentration of DP4 (300 M) was further increased by 10 M FK-506, the extent of which was similar to that of the control (Fig. 5B) . This was also true with RyR1 treated with 2% CHAPS (Fig. 5B) , the effect of which was independent of FKBP12 (19) . Taken together, these results suggest that DP4 as well as CHAPS activates RyR1 through the mechanism independent of FKBP12-RyR1 interaction.
Effect of DP4 on single Ca 2ϩ release channel activity in native SR and purified RyR1. Single-channel currents through the RyR1 channel were recorded in symmetrical solutions containing 250 mM KCl (or Cs-methanesulfonate) at a holding potential of Ϫ40 mV (see MATERIALS AND METHODS). We used both the native SR vesicles and purified RyR1. Although RyR1 has bound calmodulin and FKBP12 in the native SR (15, 24) , the purified RyR1 is free of such associated proteins (17) . With the native SR vesicles, 10 M DP4 increased mean P o of the channel (Fig. 6A, left) . A further increase in P o was observed with 30 M DP4. With the purified RyR1, DP4 also activated the channel in a concentration-dependent manner (Fig. 6A,  right) . No significant change in the current amplitude was observed in either specimen. There was no difference between the purified RyR1 and the native SR vesicles with regard to the magnitude of activation by DP4 (Fig. 6B) . Although the purified RyR1 contained 1% CHAPS, the detergent concentration had to be reduced to a negligible level when RyR1 was incorporated into the lipid bilayer. On the basis of the results shown in Fig. 2B , the effect of CHAPS is expected to be reversible. These findings suggest that DP4 directly activates RyR1 without any requirement of accessory modulators.
Effect of DP4 on the responses of RyR1 to various modulators of CICR. We have shown that the stabilization of the RyR1 channel may be attributed primarily to a reduction in the gain of CICR activity, but not to an alteration in its response to the CICR modulators (19 (Fig. 8A , open circles). The ryanodine binding was increased seven-to eightfold by 100 M DP4 at all AMPPCP concentrations (Fig.  8A, closed circles) . Normalized values (Fig. 8A, inset) revealed that there was no significant difference in the activation pattern associated with AMPPCP; the EC 50 value, 0.3 mM, was about the same under both conditions. This suggests that DP4 does not affect the sensitivity of RyR1 to adenine nucleotide. The concentration dependence of caffeine activation is shown in Fig. 8B . Caffeine increased the binding at 1 M Ca 2ϩ in a concentration-dependent manner (Fig. 8B, open circles) . The ryanodine binding was further enhanced by 100 M DP4 at all caffeine concentrations used (Fig. 8B, closed circles) . In addition, DP4 slightly sensitized RyR1 to caffeine; the EC 50 value for caffeine with 100 M DP4 (ϳ1.2 mM) was about half that of the control (ϳ2.4 mM) (Fig. 8B, inset) .
Effect of DP4 on Ca 2ϩ release from isolated SR vesicles. Ca 2ϩ release from the isolated SR vesicles was fluorometrically determined with the bovine epicranial muscle SR (see MATERIALS AND METHODS). DP4 induced transient Ca 2ϩ release from the Ca 2ϩ -loaded SR, and this effect was concentration dependent, although the releasing action was weak (Fig. 9A) . Caffeine also induced concentration-dependent Ca 2ϩ release: Ca 2ϩ release was marginal at 2 mM caffeine and massive at 10 mM caffeine (Fig. 9B, left) . Pretreatment with 30 M DP4 markedly enhanced Ca 2ϩ release by 2 mM caffeine, but not with 10 mM caffeine (Fig. 9B, right) . This potentiating effect of 30 M DP4 was examined in the presence of various concentrations of caffeine (Fig. 9C) . The threshold concentration of caffeine was decreased from ϳ1 mM in the absence of DP4 to ϳ0.2 mM in the presence of 30 M DP4. The potentiating effect of DP4, however, appeared to decrease with an increase in the caffeine concentration. This is probably due to the limitation of the amount of releasable Ca 2ϩ stored in the SR, because the amount of Ca 2ϩ released by 10 mM caffeine alone (open circle) was similar to that obtained with simultaneous addition of caffeine and DP4 (reversed triangle). Taken together, these findings suggest that DP4 sensitizes the RyR1 channel to caffeine in releasing Ca 2ϩ from the SR.
DISCUSSION
Our recent work showed that the CICR activity of RyR1 was considerably lower than that of RyR3 in native SR vesicles, whereas after CHAPS treatment, the two purified isoforms showed equal activity with unchanged Ca 2ϩ sensitivity (19) . dependence. Experiments were performed as in Fig. 2A at various Ca 2ϩ concentrations in the presence (closed circles) and absence (open circles) of 100 M DP4. Data are means Ϯ SE; n ϭ 3. Inset: Ca 2ϩ dependence was compared after normalization to the respective peak values. Note that DP4 greatly increased the binding at all Ca 2ϩ concentrations examined. However, it slightly increased the Ca 2ϩ sensitivity in Ca 2ϩ activation, whereas it did not affect the Ca 2ϩ dependence for Ca 2ϩ inactivation. B: Mg 2ϩ dependence. Experiments were performed as in Fig. 2A with 0 -10 Sensitivity to adenine nucleotide was unchanged. RyR1, but not RyR3, is therefore considered to be in the stabilized state in the SR, where the gain of CICR is reduced. Although removal of FKBP12 partly (Ͻ30%) explained the stabilization, the remaining major part was reversed by CHAPS, indicating critical involvement of molecular interactions. Ikemoto and colleagues (10, 32, 36) showed that DP4, a synthetic peptide corresponding to the Leu 2442 -Pro 2477 region, stimulated RyR1 activity, but that DP4-mut observed in MH did not. They proposed a hypothesis that an interdomain interaction between the NH 2 -terminal domain and the central domain containing the DP4 region regulates channel activity and that "unzipping" of the interacting domains destabilized the channel, resulting in enhanced Ca 2ϩ release activity observed in MH (5, 6).
The main aim of the present study was to test whether the hypothesized interdomain interaction is involved in the CHAPS-induced activation and/or destabilization of the RyR1 channel. We examined the effects of CHAPS and DP4 on RyR1 of bovine skeletal muscle SR vesicles using a [
3 H]ryanodine binding assay. We have demonstrated that 1) DP4 and CHAPS activated RyR1 but not RyR3 (Fig. 1); 2) the two reagents showed the identical level of maximal activation (Fig.  2) , and these activation effects were nonadditive (Fig. 3); 3) RyR1 activated by DP4 or CHAPS was inhibited by dantrolene and azumolene, showing an identical pattern of inhibition (Fig.  4) ; and 4) activation by DP4 or CHAPS was independent of FKBP12-dependent stabilization (Fig. 5) . All of these findings suggest that DP4 and CHAPS share a common mechanism for the activation of RyR1.
An increasing body of evidence supports the hypothesis that the interactions between the two key domains harboring many of the reported MH mutations (NH 2 -terminal and central domains) play an important role in the regulation of RyR1 Ca 2ϩ channels. Thus domain peptides and antibodies that bind specifically to either of these domains produced MH-like hyperactivation and hypersensitization of RyR1 channels (8, 10, 32, 36) . The channel activation by these agents is well correlated with increased accessibility of the fluorescent probe, attached to either of these domains, to a macromolecular fluorescence quencher, indicative of an increased gap between the interacting domains, namely, domain unzipping (8, 37) . Furthermore, dantrolene that binds to the Leu 590 -Cys 609 region of the NH 2 -terminal domain of RyR1 (28) inhibited DP4-and anti-DP4 antibody-induced channel activation, accompanied by a decrease in the probe accessibility to the quencher (i.e., a decrease in the gap of the interacting domains, or domain zipping) (7). As described above, CHAPS-and DP4-induced channel activation share various common features in the process of not only channel activation but also channel inhibition by dantrolene. Thus it seems that the actual mechanism of CHAPS-induced activation and/or destabilization of the RyR1 channel is mediated by destabilization of the interacting domain pair consisting of the NH 2 -terminal and central domains. It is likely, then, that the hypothesized interdomain interaction is affected by CHAPS, resulting in enhanced activity of RyR1, the effect that is indistinguishable from the one caused by DP4. However, little is known about how the conformational signal elicited in the interacting domains can be transmitted to the channel, although there must be some mechanisms by which the channel is functionally coupled with the operation of these domains. There remains a strong possibility that DP4 and CHAPS change allosteric domain-domain and domain-channel interactions, reducing the free energy barrier to facilitate the change from the closed to the open state of the channel.
We previously proposed that the stabilization of RyR1 might cause reduction in the gain of CICR activity because the ligand sensitivity remains unchanged in the SR vesicles (19) (Fig. 7B ), or activating AMPPCP (Fig. 8A ), whereas slight sensitization was observed with activating Ca 2ϩ (ϳ1.5-fold) (Fig. 7A) or caffeine (ϳ2-fold) (Fig. 8B) . The enhancing effect of DP4 with slight sensitization was also reported with rabbit skeletal muscle SR (36) . These results suggest that the primary effect of DP4 is to increase the gain of CICR activity. This supports our hypothesis that the stabilization of RyR1 primarily causes the reduction in gain of CICR.
The importance of the CICR gain seems to have been overlooked often in previous investigations. It is difficult to compare CICR activity directly between different samples (e.g., SR vesicles from different tissues or cells expressing different RyR mutants) because of different RyR contents. Therefore, comparisons generally have been made after normalization of the activity with its peak activity (e.g., [ 3 H]ryanodine binding at the optimum Ca 2ϩ ) (see Fig. 7 , A and B) to correct for the RyR contents. Such normalization is useful for determining the sensitivity to ligands (e.g., Ca 2ϩ , Mg 2ϩ , or caffeine) but may lead to misinterpretation of the CICR gain. We could overcome this problem by using the B/B max expression, which reflects apparent average activity of individual channels and holds the information about CICR gain (19) . Thus the B/B max expression connoting the CICR gain is useful for the evaluation of CICR activity.
The concept of CICR gain may also explain some species differences with regard to caffeine sensitivity. For instance, it was found that caffeine easily causes contracture of frog skeletal muscle, but that it often is abortive in mammalian skeletal muscle (25, 35) . In frog skeletal muscle, ␤-RyR may account for most of the CICR activity because it shows a B/B max value (0.2-0.25) greater than that for ␣-RyR (as low as 0.009) (20) ] i ) was set at 0.2 mM, but not when it was set at 1 mM, suggesting that the Ca 2ϩ -releasing effect of DP4 by itself does not occur at physiological [Mg 2ϩ ] i level, which was assumed to be ϳ1 mM. In the present study, DP4 induced small, transient Ca 2ϩ release from the SR vesicles (Fig. 9A) (10) (Fig. 9) . These features correlate well with the characteristics of MH, in which muscle contracture or Ca 2ϩ release may occur only when it is exposed to specific drugs such as halothane or caffeine (16, 21) . Thus the enhanced CICR activity induced by DP4 is likely to mimic the altered Ca 2ϩ handling observed in the MH phenotype. The findings to date also imply that the low CICR gain of the RyR1 channel is critically important in normal Ca 2ϩ handling in skeletal muscle.
